In vitro and in vivo comparison between crystalline and co-amorphous salts of naproxen-arginine

Georgia Kasten, Lonita Lobo, Swapnil Dengale, Holger Grohganz, Thomas Rades, Korbinian Löbmann

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Liquid-assisted grinding (LAG) and dry ball milling (DBM) have recently been used to obtain different physical forms of drug-amino acid salts with promising dissolution and physical stability properties. In this work, crystalline and co-amorphous naproxen-arginine mixtures were prepared using LAG and DBM, respectively, and compared with regard to their in vitro and in vivo performance. X-ray powder diffraction and Fourier-transformed infrared spectroscopy showed that LAG led to the formation of a crystalline salt, while DBM led to a co-amorphous salt. These results agreed with the differential scanning calorimetry profiles: a melting point of 230 °C was determined for the crystalline salt, while the co-amorphous formulation showed a single glass transition temperature at approx. 92 °C. Both solid state forms of the salt showed increased intrinsic dissolution rates (14.8 and 74.1-fold, respectively) and also higher solubility (25.3 and 29.8-fold, respectively) compared to the pure crystalline drug in vitro. Subsequently, the co-amorphous salt revealed an improved bioavailability in a pharmacokinetic study, showing a 1.5-fold increase in AUC0-t and a 2.15-fold increase in cmax compared to the pure crystalline drug. In contrast, even though showing a better in vitro performance, the crystalline salt interestingly did not show an increase in bioavailability in comparison to pure crystalline naproxen.

Original languageEnglish
Pages (from-to)192-199
Number of pages8
JournalEuropean Journal of Pharmaceutics and Biopharmaceutics
Volume132
DOIs
Publication statusPublished - 01-11-2018

Fingerprint

Naproxen
Arginine
Salts
Biological Availability
Pharmaceutical Preparations
Powder Diffraction
Transition Temperature
Differential Scanning Calorimetry
In Vitro Techniques
X-Ray Diffraction
Solubility
Freezing
Glass
Spectrum Analysis
Pharmacokinetics
Amino Acids

All Science Journal Classification (ASJC) codes

  • Biotechnology
  • Pharmaceutical Science

Cite this

Kasten, Georgia ; Lobo, Lonita ; Dengale, Swapnil ; Grohganz, Holger ; Rades, Thomas ; Löbmann, Korbinian. / In vitro and in vivo comparison between crystalline and co-amorphous salts of naproxen-arginine. In: European Journal of Pharmaceutics and Biopharmaceutics. 2018 ; Vol. 132. pp. 192-199.
@article{6cc1c56c6ce94d91aa17cd4b083b2e45,
title = "In vitro and in vivo comparison between crystalline and co-amorphous salts of naproxen-arginine",
abstract = "Liquid-assisted grinding (LAG) and dry ball milling (DBM) have recently been used to obtain different physical forms of drug-amino acid salts with promising dissolution and physical stability properties. In this work, crystalline and co-amorphous naproxen-arginine mixtures were prepared using LAG and DBM, respectively, and compared with regard to their in vitro and in vivo performance. X-ray powder diffraction and Fourier-transformed infrared spectroscopy showed that LAG led to the formation of a crystalline salt, while DBM led to a co-amorphous salt. These results agreed with the differential scanning calorimetry profiles: a melting point of 230 °C was determined for the crystalline salt, while the co-amorphous formulation showed a single glass transition temperature at approx. 92 °C. Both solid state forms of the salt showed increased intrinsic dissolution rates (14.8 and 74.1-fold, respectively) and also higher solubility (25.3 and 29.8-fold, respectively) compared to the pure crystalline drug in vitro. Subsequently, the co-amorphous salt revealed an improved bioavailability in a pharmacokinetic study, showing a 1.5-fold increase in AUC0-t and a 2.15-fold increase in cmax compared to the pure crystalline drug. In contrast, even though showing a better in vitro performance, the crystalline salt interestingly did not show an increase in bioavailability in comparison to pure crystalline naproxen.",
author = "Georgia Kasten and Lonita Lobo and Swapnil Dengale and Holger Grohganz and Thomas Rades and Korbinian L{\"o}bmann",
year = "2018",
month = "11",
day = "1",
doi = "10.1016/j.ejpb.2018.09.024",
language = "English",
volume = "132",
pages = "192--199",
journal = "European Journal of Pharmaceutics and Biopharmaceutics",
issn = "0939-6411",
publisher = "Elsevier",

}

In vitro and in vivo comparison between crystalline and co-amorphous salts of naproxen-arginine. / Kasten, Georgia; Lobo, Lonita; Dengale, Swapnil; Grohganz, Holger; Rades, Thomas; Löbmann, Korbinian.

In: European Journal of Pharmaceutics and Biopharmaceutics, Vol. 132, 01.11.2018, p. 192-199.

Research output: Contribution to journalArticle

TY - JOUR

T1 - In vitro and in vivo comparison between crystalline and co-amorphous salts of naproxen-arginine

AU - Kasten, Georgia

AU - Lobo, Lonita

AU - Dengale, Swapnil

AU - Grohganz, Holger

AU - Rades, Thomas

AU - Löbmann, Korbinian

PY - 2018/11/1

Y1 - 2018/11/1

N2 - Liquid-assisted grinding (LAG) and dry ball milling (DBM) have recently been used to obtain different physical forms of drug-amino acid salts with promising dissolution and physical stability properties. In this work, crystalline and co-amorphous naproxen-arginine mixtures were prepared using LAG and DBM, respectively, and compared with regard to their in vitro and in vivo performance. X-ray powder diffraction and Fourier-transformed infrared spectroscopy showed that LAG led to the formation of a crystalline salt, while DBM led to a co-amorphous salt. These results agreed with the differential scanning calorimetry profiles: a melting point of 230 °C was determined for the crystalline salt, while the co-amorphous formulation showed a single glass transition temperature at approx. 92 °C. Both solid state forms of the salt showed increased intrinsic dissolution rates (14.8 and 74.1-fold, respectively) and also higher solubility (25.3 and 29.8-fold, respectively) compared to the pure crystalline drug in vitro. Subsequently, the co-amorphous salt revealed an improved bioavailability in a pharmacokinetic study, showing a 1.5-fold increase in AUC0-t and a 2.15-fold increase in cmax compared to the pure crystalline drug. In contrast, even though showing a better in vitro performance, the crystalline salt interestingly did not show an increase in bioavailability in comparison to pure crystalline naproxen.

AB - Liquid-assisted grinding (LAG) and dry ball milling (DBM) have recently been used to obtain different physical forms of drug-amino acid salts with promising dissolution and physical stability properties. In this work, crystalline and co-amorphous naproxen-arginine mixtures were prepared using LAG and DBM, respectively, and compared with regard to their in vitro and in vivo performance. X-ray powder diffraction and Fourier-transformed infrared spectroscopy showed that LAG led to the formation of a crystalline salt, while DBM led to a co-amorphous salt. These results agreed with the differential scanning calorimetry profiles: a melting point of 230 °C was determined for the crystalline salt, while the co-amorphous formulation showed a single glass transition temperature at approx. 92 °C. Both solid state forms of the salt showed increased intrinsic dissolution rates (14.8 and 74.1-fold, respectively) and also higher solubility (25.3 and 29.8-fold, respectively) compared to the pure crystalline drug in vitro. Subsequently, the co-amorphous salt revealed an improved bioavailability in a pharmacokinetic study, showing a 1.5-fold increase in AUC0-t and a 2.15-fold increase in cmax compared to the pure crystalline drug. In contrast, even though showing a better in vitro performance, the crystalline salt interestingly did not show an increase in bioavailability in comparison to pure crystalline naproxen.

UR - http://www.scopus.com/inward/record.url?scp=85054074902&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054074902&partnerID=8YFLogxK

U2 - 10.1016/j.ejpb.2018.09.024

DO - 10.1016/j.ejpb.2018.09.024

M3 - Article

VL - 132

SP - 192

EP - 199

JO - European Journal of Pharmaceutics and Biopharmaceutics

JF - European Journal of Pharmaceutics and Biopharmaceutics

SN - 0939-6411

ER -